ReviewFrontiers in immunology2019
NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 68 citations in OpenAlex.
- In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy.Frontiers in immunology · 2023Trial
- Innate Lymphoid Cells Activation and Transcriptomic Changes in Response to Human Dengue Infection.Frontiers in immunology · 2021Trial
- Phenotypic shift of small intestinal intra-epithelial type 1 innate lymphoid cells in celiac disease is associated with enhanced cytotoxic potential.Clinical and experimental immunology · 2020Trial
- From single cell analysis to 3D micro physiological systems: microfluidic tools integrating cancer cell targets for delineating natural killer cell biology.Microsystems & nanoengineering · 2026Review
- Transcriptional Profile Change of NK-92 Cells in Presence of Cytokines, TGFβ Signaling Pathway Inhibitor and CDK7/12/13 Kinase Inhibitor.International journal of molecular sciences · 2026Article
- Coexpression of GITRL confers resistance to Treg cell-mediated immunosuppression to anti-CD19 CAR-NK cells.Frontiers in immunology · 2026Article
- Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers.Frontiers in immunology · 2026Article
- Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases.Cancer metastasis reviews · 2025Review
- Cytokine-induced memory-like natural killer cells in systemic lupus erythematosus patients.Advances in rheumatology (London, England) · 2025Article
- Allelic bias contributes to heterogeneous phenotypes of NK cell deficiency.Cell reports · 2025Article
- Cytotoxic Responses Mediated by NK Cells and Cytotoxic T Lymphocytes in Xenotransplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Current Developments in NK Cell Engagers for Cancer Immunotherapy: Focus on CD16A and NKp46.Immune network · 2024Review
- Ligand requirements for immunoreceptor triggering.Communications biology · 2024Article
- Natural Killer cells at the frontline in the fight against cancer.Cell death & disease · 2024Review
- Review
- Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Functional TRPA1 Channels Regulate CD56International journal of molecular sciences · 2023Article
- Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.Molecular cancer · 2023Review
- Alterations in the immune system persist after one year of convalescence in severe COVID-19 patients.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural Killer (NK) cells are potent cytotoxic cells belonging to the family of Innate Lymphoid Cells (ILCs). Their most characterized effector functions are directed to the control of aberrant cells in the body, including both transformed and virus-infected cells. NK cell-mediated recognition of abnormal cells primarily occurs through receptor-ligand interactions, involving an array of inhibitory and activating NK receptors and different types of ligands expressed on target cells. While most of the receptors have become known over many years, their respective ligands were only defined later and their impressive complexity has only recently become evident. NKp44, a member of Natural Cytotoxicity Receptors (NCRs), is an activating receptor playing a crucial role in most functions exerted by activated NK cells and also by other NKp44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.